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The value of PET/CT with FES or FDG tracers
in metastatic breast cancer: a computer
simulation study in ER-positive patients
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Background: The aim of this study was to evaluate the effect on the number of performed biopsies and costs associated with
implementing positron emission tomography (PET) and computed tomography (PET/CT) with 16a-[18F]fluoro-17b-oestradiol (FES)
or 2-[18F]fluoro-2-deoxy-D-glucose (FDG) as an upfront imaging test for diagnosing metastatic breast cancer (MBC) in comparison
with the standard work-up in oestrogen receptor-positive women with symptoms.
Methods: A published computer simulation model was adapted and validated. Three follow-up strategies were evaluated in a
simulated cohort of women with primary breast cancer over a 5-year-time horizon: (1) the standard work-up, (2) upfront FES-PET/
CT and (3) upfront FDG-PET/CT. The main outcome was the number of avoided biopsies to assess MBC. The costs for all three
strategies were calculated based on the number of imaging tests and biopsies. The incremental cost-effectiveness ratio (ICER) to
avoid a biopsy was calculated only based on the costs of initial imaging and staging tests.
Results: The FES-PET/CT strategy decreased the number of biopsies by 39±9%, while upfront FDG-PET/CT increased the
number of biopsies by 38±15% when compared with the standard work-up. Both PET/CT strategies reduced the number of
imaging tests and false positives when compared with the standard work-up. The number of false negatives decreased only in the
FES-PET/CT strategy. The ICER in the FES-PET/CT strategy per avoided biopsy was 12.1±3.4 thousand Euro. In the FDG-PET/CT
strategy, the costs were higher and there were no avoided biopsies as compared with the standard work-up, hence this was an
inferior strategy in terms of cost effectiveness.
Conclusions: The number of performed biopsies was lower in the FES-PET/CT strategy at an ICER of 12.1±3.4 thousand Euro per
biopsy avoided, whereas the application of the FDG-PET/CT did not reduce the number of biopsies and was more expensive.
Whether the FES-PET/CT strategy has additional benefits for patients in terms of therapy management has to be evaluated in
clinical studies.
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In the Netherlands, the crude rate for breast cancer mortality has
fallen from 44.9 to 37.8 death cases per 100 000 in the past two
decades, and nowadays the 5-year age-adjusted relative survival is
82% (IKNL, 2014). Around 10% of all breast cancer patients will
develop metastatic breast cancer (MBC) within 5 years after
primary diagnosis (Lord et al, 2012). The incidence of MBC is
highest in the first 2 years, slowly decreases till the fifth year and
remains relatively constant thereafter (Miller, 2003; Lord et al,
2012). The most common sites for MBC are bone, lung/pleura,
liver, lymph nodes and brain (Miller, 2003; Sihto et al, 2011;
Lord et al, 2012).
According to the clinical guidelines of the European Society for
Medical Oncology and the National Comprehensive Cancer
Network (NCCN Guidelines Version 3, 2014), the standard
work-up for diagnosing MBC includes conventional imaging with
bone X-ray and/or bone scintigraphy, chest X-ray and/or chest
computed tomography (CT), liver ultrasound and/or abdominal
CT, and magnetic resonance imaging (MRI). Histological biopsies
are advised to confirm findings and re-evaluate tumour receptor
status of MBC (oestrogen receptor (ER), progesterone receptor,
human epidermal growth factor receptor 2 (HER2; Cardoso et al,
2012; NCCN Guidelines Version 3, 2014). However, biopsies can
be difficult to obtain owing to the location of the metastasis and
results can be inconclusive regarding the receptor status, which
hampers optimal treatment (Hammond et al, 2010).
When findings on conventional imaging are equivocal or in
locally advanced inoperable breast cancer, positron emission
tomography (PET) and CT (PET/CT) with 2-[18F]fluoro-2-
deoxy-D-glucose (FDG) is an acceptable option to further evaluate
suspected MBC (Grassetto et al, 2011; Cardoso et al, 2012; NCCN
Guidelines Version 3, 2014; Cardoso et al, 2014).
Positron emission tomography imaging with the novel tracer
16a-[18F]fluoro-17b-oestradiol (FES) can give insight in tumour
ER expression in breast cancer (Peterson et al, 2008), and has high
sensitivity for bone (92%) and lung lesions (95%; Van Kruchten
et al, 2013). FES-PET was found to improve the diagnosis and
treatment decision making in patients with a history of ER-positive
breast cancer presenting with a clinical dilemma on conventional
imaging (Van Kruchten et al, 2012). It should be noted that a
negative FES-PET does not rule out tumour, as ER-negative
metastases are not visible on FES-PET. The combination of FES-
PET and CT may, however, largely overcome this issue by giving
insights in tumour lesions on CT that are FES negative. To our
knowledge, the effect of upfront PET/CT with the tracers FES and
FDG on the number of performed biopsies and associated costs has
so far not been examined.
The aim of this study was, therefore, to evaluate the effect on
the number of performed biopsies and costs associated with
implementing FES or FDG-PET with contrast-enhanced CT as an
upfront imaging test for diagnosing ER-positive MBC in
comparison with the standard work-up in women presenting with
symptoms.
MATERIALS AND METHODS
A previously published and validated computer simulation model was
extended and validated to reflect diagnosing of MBC (Jacobi et al, 2006;
Greuter et al, 2010; Lu et al, 2012; De Bock et al, 2013). The model was
constructed to simulate the follow-up of women after a diagnosis of
initial breast cancer with ER-positive receptor status of the primary
tumour. The main outcome was the number of avoided biopsies.
The Medical Ethical Committee of the University Medical
Center Groningen concluded that no formal approval for this
project was needed, as it was not a medical research study that
involved humans. Informed consent from patients was not needed.
Structure of the model. The structure of the simulation model and
its parameters are presented in Figures 1–3 and Tables 1 and 2.
Every year a woman might die, might develop symptoms and MBC
or might develop symptoms suggestive for MBC without actual
disease. The model first evaluated whether a woman would die,
using age and general death rate. In case of death, the woman exited
the loop. Otherwise, the presence of MBC was simulated based on
the risk to develop MBC over time and distributed over the four
locations. If MBC was present, the woman developed symptoms at
the specific location(s) of the MBC(s). However, if no MBC was
present, symptoms suggestive for MBC could still be present
depending on the risk to develop such symptoms per year (Table 1).
In the absence of symptoms, the woman’s age was increased by 1
year and the loop was repeated. If presenting with symptoms, with
or without underlying MBC, the woman was subjected to a
diagnostic strategy. When actual MBC was diagnosed (as confirmed
by a positive biopsy or a positive FES-PET/CT) the woman exited
the simulation. If the woman was not diagnosed with MBC, either
due to false symptoms or false-negative test results, her age was
increased and she re-entered the loop.
Strategies for detecting MBC. Three diagnostic strategies for
detecting symptomatic MBC were compared (Figures 1–3). The
standard work-up was based on the Dutch clinical guidelines and
included the recommended tests, that is, X-ray, bone scintigraphy,
CT, ultrasound, MRI and biopsies (Mammacarcinoom Landelijke
richtlijn, Version 2.0, 2014; Figure 1).
In the FES-PET/CT strategy, whole-body FES-PET/CT replaced
the conventional imaging tests as upfront diagnostic for sympto-
matic MBC. In case of positive FES-PET/CT, no biopsy procedures
were performed. When the FES-PET/CT was negative and there
were no longer (at 3 months) symptoms suggestive for MBC, the
patients exited the loop without further testing. In case of negative
or inconclusive FES-PET/CT and persistent MBC symptoms,
conventional imaging and biopsies were added to exclude the
option of ER-negative MBC (Figure 2).
In the FDG-PET/CT strategy, patients followed the same route
and diagnostic sequence as in the FES-PET/CT, but whole-body
FDG-PET/CT was the upfront diagnostic test. As the FDG-PET/CT
was not informative of the MBC receptor status, biopsies still had
to be performed in case of positive FDG-PET/CT (Figure 3).
The parameters of the model. The model incorporated seven
parameters (Table 1) with distinctive baseline, minimum and
maximum estimates derived from literature. The risk to develop
MBC and the incidence distribution was calculated from a study
including 6644 patients diagnosed with breast cancer in the period
2001–2002 and followed till the end of 2007 (Lord et al, 2012). The
yearly risk to develop symptoms suggestive for MBC and its
distribution over the four locations was based on the observed
referral rate to diagnostic services in primary care cancer survivors,
which could be considered a good proxy for the incidence of such
symptoms in this population (Roorda et al, 2012; Christensen et al,
2012). The death rate model was based on the cumulative death
rates at ages up to 100 years for the Dutch cohort born in 1970
(Lu et al, 2012; De Bock et al, 2013). The model contained the
mean sensitivity and specificity of the imaging modalities
independent of age (Table 2; Radan et al, 2006; Weber et al,
2006; Ellika et al, 2007; Mahner et al, 2008; Costelloe et al, 2009;
Floriani et al, 2010; Hahn et al, 2011; Evangelista et al, 2012;
Houssami and Costelloe, 2012; Murakami et al, 2012; Hendriks
et al, 2013; National Lung Screening Trial Research Team, 2013;
Sadigh et al, 2014). The specificity of FES-PET was based on earlier
studies that compared FES-uptake with tumour biopsies, with
either qualitative assessment of FES-uptake or quantitative
assessment with a maximum standardised uptake value (SUVmax)
threshold of X1.0 (Van Kruchten et al, 2013). The inconclusive
rates of imaging tests and biopsies were based on expert opinion.
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The model validation. To validate the model, a cohort of all
female patients diagnosed and treated with ER-positive primary
breast cancer in the period 2000–2002 at our hospital was
identified (n¼ 108) and followed for 5 years.
The simulation. To evaluate the strategies for detecting MBC, a
cohort of women treated for primary breast cancer was simulated.
The ages of breast cancer diagnosis in this cohort were derived
from a cohort of 5073 women diagnosed with and treated for
breast cancer between January 1989 and January 2003 in four
hospitals in the Netherlands (one academic hospital, one large
teaching hospital and two non-teaching hospitals). The women
were representative for the Dutch breast cancer population with
respect to their age at diagnosis (61.1±14.4 years; Lu et al, 2012).
Sensitivity analysis. A sensitivity analysis was performed to test the
effect of the uncertainty regarding input estimates on model output.
A normal distribution of all parameters was assumed with minimum
and maximum estimates equal to the 95% confidence interval
around the baseline. For each parameter, a random value was
obtained from the normal distribution. The simulations for the three
scenarios were performed with 10 data sets for 5073 women and for
20 simulation rounds. For the validation, the simulation data was
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Figure 1. Structure of the MBCSIM simulation model for the standard work-up. Women enter the simulation with bone, lung, liver and/or brain
symptoms. The triangles indicate questions with output indicators Y¼ yes and N¼ no. The squares indicate imaging tests with output indicators,
þ denotes positive,  denotes negative and ± denotes inconclusive.
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scaled to represent the outcomes for 108 women. All outcomes were
presented in terms of mean and s.d. (Tables 3 and 4).
Costs. Cost parameters included the unit prices of the tests based
on tariffs (Table 2; NZA, 2014). The price level of 2013 was applied
and valued in Euros (h). Only direct costs related to diagnosing
MBC were considered. Discounting was not applied.
Economic analysis of model outcomes. The total costs for the
strategies were computed by summing the costs of all performed tests.
The incremental cost-effectiveness ratio (ICER) was calculated by
dividing the additional costs of the alternative strategies resulting from
initial imaging and staging tests by the number of avoided biopsies.
RESULTS
Validation of the model. The simulation model reproduced
sufficiently the number of initial tests and biopsies, whose actual
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Figure 2. Structure of the MBCSIM simulation model for the FES-PET/CT strategy. Women enter the simulation with bone, lung, liver and/or
brain symptoms. The triangles indicate questions with output indicators Y¼ yes and N¼no. The squares indicate imaging tests with output
indicators, þ denotes positive,  denotes negative and ± denotes inconclusive. In case of multimodality imaging (i.e., FES-PET and CT), each
individual modality can have these three outcomes, leading to nine possible outcomes for the combined modality (i.e., FES-PET/CT).
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observed values were in the models’ confidence intervals
(104.0±6.5 vs 116 and 20.3±1.5 vs 18). The model slightly
overestimated the staging tests (17.9±1.3 vs 13) and under-
estimated the MBCs (10.2±1.0 vs 14; Table 3).
Clinical effects. The replacement of the standard testing by FES-PET/
CT decreased the total number of biopsies by 39±9% as compared
with the standard work-up, whereas the FDG-PET/CT increased the
number of biopsies by 38±15% in comparison with standard care.
The number of false-negative results decreased only in the
FES-PET/CT strategy by 13±15% compared with the standard
work-up and by 17±16% compared with the FDG-PET/CT
strategy.
The application of FES-PET/CT decreased the number of false
positives by 58±12% compared with the standard work-up and by
44±15% compared with the FDG-PET/CT strategy, while in the
FDG-PET/CT the false positives decreased by 26±22% compared
with the standard work-up.
FDG-PET+CT
Bone scan MRI bone
Biopsy 
Bone symptoms
+3 months?
BiopsyY
N
–/–
–/+, ± /+, +/+, +/–, +/±
Y
N
+
±
Y–
N
± /+
–
– –
±
+
+
Bone symptoms?
Bone symptoms
+3 months?
Enter
Re-enter
Exit
– /±, ± /±, ± /–
FDG-PET+CT Biopsy Biopsy
Y
N
–/+, ± / +, +/+, +/–, +/±
–
– –
±
+
+
Lung symptoms?
Enter
Re-enter
Exit
–/–, –/±, ± /±, ± / –
FDG-PET+CT
MRI liver
Biopsy
Liver symptoms
+3 months?
BiopsyY
N
–/–
–/+, ± /+, +/+, +/–, +/±
Y
N
+
–, ±
–
– –
±
+
+
Liver symptoms?
Enter
Re-enter
Exit
–/±, ± /±, ± /–
MRI brain
Biopsy 
Brain symptoms
+3 months?
Biopsy Y
N
Y
N
– –
±
+
+
Brain symptoms?
Enter
Re-enter
Exit
FDG-PET+CT
–/–
–/+, ± /+, +/+, +/–, +/±
–/±, ± /±, ± /–
–, ±
+
Figure 3. Structure of the MBCSIM simulation model for the FDG-PET/CT strategy. Women enter the simulation with bone, lung, liver and/or
brain symptoms. The triangles indicate questions with output indicators Y¼ yes and N¼no. The squares indicate imaging tests with output
indicators, þ denotes positive,  denotes negative and± denotes inconclusive. In case of multimodality imaging (i.e., FDG-PET and CT), each
individual modality can have these three outcomes, leading to nine possible outcomes for the combined modality (i.e., FDG-PET/CT).
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Economic analysis. The total costs for the FES-PET/CT strategy
were higher as compared with the standard work-up and the FDG-
PET/CT strategy, although the total number of performed tests
decreased in both PET/CT strategies as compared with the
standard work-up (FES-PET/CT: 9±6% and FDG-PET/CT:
56±3%). The ICER to avoid an additional biopsy in the FES-
PET/CT over the standard work-up was calculated at 12.1±3.4
thousand Euros. The FDG-PET/CT did not avoid biopsies and the
costs were higher compared with the standard work-up, and it was
a dominated strategy (Table 4).
DISCUSSION
The aim of this study was to evaluate the effect on the number of
performed biopsies and costs associated with implementing
PET/CT with FES or FDG as an upfront imaging test for
diagnosing ER-positive MBC as compared with the standard
work-up in women with symptoms. A previously applied and
validated simulation model was expanded and revalidated for this
study. The model proved to be sufficiently valid for reproducing
the cohort results, which made it suitable for performing this
economic evaluation. The PET/CT strategies yielded higher
additional costs to diagnose MBC, although the total number of
tests decreased as compared with the standard work-up. The
number of false positives decreased in both PET/CT strategies.
Biopsies were avoided and false negatives were decreased only in
the FES-PET/CT strategy.
Novel diagnostic tests and therapies not only improved the
survival rate among cancer patients in the last decades but also
increased health-care expenditures (RIVM report, 2012), so prior
evaluation of costs and effects is warranted. Combined PET/
contrast-enhanced CT was suggested to provide a noninvasive
evaluation of MBC in a single procedure (Pennant et al, 2010). This
study showed that the PET/CT strategies decreased the number of
imaging tests and thus could reduce the associated hospital visits,
time off work and time to diagnosis.
The FES-PET/CT strategy decreased the number of false-
negative diagnoses that could avoid potential delay in treatment
and relief of symptoms. In addition, the FES-PET/CT strategy
decreased the number of obtained biopsies and thus the number of
painful and invasive episodes for patients. The sensitivity of
Table 1. Parameters of the simulation model
Baseline
estimate
(%)
Minimum
estimate
(%)
Maximum
estimate
(%) Reference
Risk to develop MBC
1st Year 1.2 1.0 1.5 Lord et al, 2012
2nd Year 2.9 2.5 3.3
3rd Year 2.7 2.3 3.1
4th Year 1.9 1.6 2.3
5th Year 1.6 1.3 1.9
Distribution of location of MBC
Bone 46 25 61 Lord et al, 2012
Lung 40 26 60
Brain 13 7 28
Liver 32 24 49
Probability of symptoms suggestive for MBC
Bone 10.0 8.1 11.8 Roorda et al, 2012;
Christensen et al,
2012
Lung 3.0 2.3 3.4
Brain 2.0 1.8 2.7
Liver 1.0 0.8 1.1
Probability of
inconclusive
biopsy
20 10 30 Expert opinion
Probability of
inconclusive
imaging
10 5 15 Expert opinion
Abbreviation: MBC¼metastatic breast cancer.
Table 2. Sensitivity and specificity percentages and costs of imaging tests based on location of the metastatic breast cancer
Bone Lung Liver Brain
Costs in h
(NZA, 2014) Reference
Sensitivity
Bone scintigraphy 80 (67–93) NA NA NA 135 (Houssami and Costelloe, 2012)
X-ray 61 (57–66) 74 (67–80) NA NA 47 (Mahner et al, 2008, National Lung Screening Trial Research
Team, 2013)
Magnetic resonance
imaging
94 (92–96) NA 81 (76–86) 96 (84–99) 251a/199b (Weber et al, 2006; Costelloe et al, 2009; Floriani et al, 2010)
Ultrasound NA NA 63 (25–87) NA 52 (Floriani et al, 2010)
Computed tomography 67 (48–80) 94 (91–96) 97 (89–100) 86 (71–93) 199 (Ellika et al, 2007; Mahner et al, 2008, National Lung
Screening Trial Research Team, 2013, Sadigh et al, 2014)
FES-PETc 91 (88–100) 90 (82–97) 20 (10–30) 46 (40–52) 1.505 Expert opinion
FDG-PET 90 (88–96) 90 (88–96) 90 (88–96) 50 (40–60) 1.505 (Radan et al, 2006; Hahn et al, 2011;Evangelista et al, 2012;
Murakami et al, 2012), Expert opinion
Specificity
Bone scintigraphy 86 (68–100) NA NA NA (Houssami and Costelloe, 2012)
X-ray 100 (99–100) 91 (91–92) NA NA (Mahner et al, 2008, National Lung Screening Trial Research
Team, 2013)
Magnetic resonance
imaging
89 (76–100) NA 97 (94–99) 62 (48–76) (Weber et al, 2006; Costelloe et al, 2009; Floriani et al, 2010)
Ultrasound NA NA 98 (96–100) NA (Floriani et al, 2010)
Computed tomography 95 (80–95) 90 (90–100) 76 (68–84) 100 (92–100) (Mahner et al, 2008, Hendriks et al, 2013; National Lung
Screening Trial Research Team, 2013, Sadigh et al, 2014)
FES-PETc 99 (98–100) 99 (98–100) 99 (98–100) 99 (98–100) Expert opinion
FDG-PET 81 (71–95) 81 (71–95) 81 (71–95) 50 (40–60) (Hahn et al, 2011; Radan et al, 2006; Evangelista et al, 2012;
Murakami et al, 2012), Expert opinion, Expert opinion
Abbreviations: ER¼oestrogen receptor; FDG¼ 2-[18F]fluoro-2-deoxy-D-glucose; FES¼ 16a-[18F]fluoro-17b-oestradiol; MRI¼magnetic resonance imaging; NA¼not applicable; PET¼positron
emission tomography. Listed are estimated averages (95% confidence interval).
aPrice per bone MRI.
bPrice per brain/liver MRI.
cThe sensitivity and specificity values presented are relevant for ER-positive patients only.
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FES-PET/CT is limited by several factors, including background
uptake, ER expression levels in the tumour and the size of the
tumour relative to the resolution of the PET camera. In our
study, patients with initially ER-positive breast cancer underwent
FES-PET only in case they presented with symptoms suggestive
for metastatic recurrence. Modern PET cameras have a spatial
resolution that can be as high as 2–4mm, provided that the
lesion has sufficient ER expression and is not obscured by the
uptake of the organ it is located in (i.e., liver). As it is unlikely
that a lesion smaller than the spatial resolution of the PET
camera would cause actual symptoms, it seems unlikely that
resolution limitations of PET has a significant impact on its
sensitivity in this study.
PET/CT strategies reduced the number of false-positive imaging
tests and the associated distress on patients. A false positive could as
well generate additional diagnostic costs in terms of further imaging
and biopsy testing to elucidate metastatic status or even unnecessary
treatment. Furthermore, FES-PET/CT may guide therapeutic
decision making (Van Kruchten et al, 2012) as it provided insights
in ER status and potential heterogeneity herein (Mortimer et al, 2001;
Linden et al, 2006; Van Kruchten et al, 2012), and thus could reduce
costs resulting from ineffective therapy.
A recent economic evaluation concluded that PET/CT was more
effective in terms of generated quality-adjusted life years (QALYs)
for true positives, false positives and true negatives than the
standard work-up for diagnosing MBC, and the ICER per QALY
was 29.700 pounds (B37.868 Euros) in a UK setting (Auguste
et al, 2011). In our study, both PET/CT strategies generated less
false positives and the FES-PET/CT generated less false negatives,
but the ICER was calculated per avoided biopsy (h12.100±3.400).
Although the simulation model reproduced the data in the
validation cohort sufficiently, some differences were observed in
the number of diagnosed bone MBCs and staging tests. A possible
explanation might be that the cohort described by Lord et al, 2012
included patients irrespective of their ER status. ER-positive
primary breast cancers showed tendency to give more often a first
relapse to the bone; however, the reported numbers (35–68%) were
not significantly different than the estimates in the simulation
(Sihto et al, 2011). Other potential explanation could be the
variation between clinical guidelines and self-reported actual
practice that was partly owing to the time gap between developing
the model and the validation cohort follow-up.
A limitation of this study was that the main evaluated outcome
was avoided biopsies and other outcomes such as QALY and
survival were not studied. Our study showed that FES-PET/CT
could potentially have a positive impact on quality of life by
decreasing the delay in relief of MBC symptoms and the negative
effect on patients’ health resulting from a biopsy or false positive.
FES-PET/CT could provide more information regarding metastatic
recurrence than conventional approach (Mortimer et al, 2001;
Linden et al, 2006; Van Kruchten et al, 2012), and might have
added value in therapy selection, individualised treatment and
follow-up resulting in increase of survival. However, the impact of
FES-PET/CT on treatment selection cannot yet be expressed in life
years saved or QALYs, as the data for such an estimate are lacking.
Only ER-positive patients were considered, in which FES-PET/CT
performs with a higher sensitivity. The ER status of the primary
tumour and its probability to change over time should be further
investigated, as it could have impact on proper patient and
treatment selection and thus affect costs. A limitation of the
FES-PET/CT strategy was that when a biopsy was avoided, no
information on the status of other tumour receptors (i.e., HER2
status) was obtained. As HER2 status of the metastatic disease is of
clinical relevance for the application of targeted therapy, the HER2
expression could be determined by PET imaging with 89Zr-
trastuzumab (Gaykema et al, 2014), which in contrast to biopsy
Table 3. Validation of the MBCSIM model in 108 ER-positive
breast cancer patients for a follow-up period of 5 years
Validation
database
Simulation
(mean±s.d.)
Initial imaging tests
116 104.0±6.5
BS and X-bone 53 52.2±3.8
MRI bone 8 15.3±2.2
FDG-PET/CT 3 1.2±0.3
X-ray lung 31 16.9±0.8
CT lung/liver 7 2.0±0.4
Ultrasound liver 7 7.0±0.3
MRI liver 0 0.2±0.1
MRI brain 7 9.2±2.5
FES-PET/CT 0 0.0±0.0
Staging tests
13 17.9±1.3
CT lungþCT liver 5 11.3±1.0
BSþCT lungþCT liver 8 6.6±0.9
Biopsy tests
18 20.3±1.5
Bone 6 7.4±1.0
Lung 10 5.6±0.5
Liver 0 3.3±0.2
Brain 2 4.0±1.0
MBCs found
14 10.2±1.0
Bone 8 3.7±0.6
Lung 3 2.7±0.3
Liver 2 2.6±0.2
Brain 1 1.2±0.3
Abbreviations: BS, bone scan; CT¼ computed tomography; ER¼oestrogen
receptor; FDG¼ 2-[18F]fluoro-2-deoxy-D-glucose; FES¼ 16a-[18F]fluoro-17b-oestradiol;
MBC¼metastatic breast cancer; MBCSIM, metastatic breast cancer simulation; MRI¼
magnetic resonance imaging; PET¼positron emission tomography.
Table 4. Simulation outcomes for the standard work-up, FES-
PET/CT and FDG-PET/CT strategies for a follow-up period of
5 years with 10 sets of data for 5073 women for 20 simulation
rounds
Standard FES-PET/CT FDG-PET/CT
Work-up
(mean±s.d.)
Strategy
(mean±s.d.)
Strategy
(mean±s.d.)
Initial imaging tests 963.19±60.0 1030.5±39.5 493.5±28.7
Staging tests 165.4±12.5 0.0±0.0 0.0±0.0
Biopsy tests 188.4±14.3 114.7±14.7 260.4±21.5
MBCs found 94.7±8.9 107.0±10.5 91.2±8.8
False-positive tests 103.9±24.4 43.1±8.0 76.4±14.8
Total costs h1000 232±15 1124±43 652±35
Additional costs h1000 NA 892±45 420±38
Saved biopsies NA 73.7±20.5 (-71.9±14.8)
ICER h1000 NA 12.1±3.4 (-5.8±2.2)a
Abbreviations: CT¼ computed tomography; ER¼oestrogen receptor; FDG¼ 2-[18F]fluoro-
2-deoxy-D-glucose; FES¼ 16a-[18F]fluoro-17b-oestradiol; ICER¼ incremental cost-effective-
ness ratio; MBC¼metastatic breast cancer; MRI¼magnetic resonance imaging; PET¼
positron emission tomography.
aThe ICER of the FDG-PET/CT over the standard work-up per avoided biopsy was negative
as the costs were higher and there were no avoided biopsies (i.e., the health effect was
negative).
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would give information about the HER2 status in all lesions in the
patient. Further study will have to point out whether adding this
marker would be cost effective particularly from a clinical
perspective. Another limitation was the follow-up period that
was simulated for only 5 years owing to the lack of data regarding
metastatic recurrence after that period.
CONCLUSIONS
The application of upfront PET/CT with FES and FDG in MBC
patients comes at additional costs. The number of performed biopsies
was lower in the FES-PET/CT strategy at an ICER of 12.1±3.4
thousand Euro, whereas the FDG-PET/CT did not reduce the
number of performed biopsies and was more expensive. Whether the
FES-PET/CT strategy has additional benefits for patients in terms of
therapy management has to be evaluated in clinical studies.
As FES-PET/CT could guide treatment selection and thus
potentially affect cost effectiveness by avoiding ineffective thera-
pies, its impact on treatment decision making in first line MBC
should be further addressed.
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